Drug intelligence / Profile preview

Aviga

Development stage: Phase 1
Lead developer: NatiVita
Modality: Small Molecules
Administration: Oral

Overview

Aviga is a pharmaceutical drug manufactured by JLLC NATIVITA, Republic of Belarus. It is a generic version of Sutent, containing 50 mg of Sunitinib. Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor. It works by inhibiting various RTKs, including all receptors for platelet-derived growth factor (PDGF-Rs), vascular endothelial growth factor receptors (VEGFRs), c-KIT (CD117), RET, and FLT3. This inhibition reduces tumor vascularization, impedes tumor growth and angiogenesis, and promotes cancer cell apoptosis.

Brand names: Aviga

Targets

KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFR (PDGFR family)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)VEGFR (VEGFR family)

Beyond the preview

Go deeper on Aviga.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aviga.

Explore the full profile